Skip to main content
Article thumbnail
Location of Repository

Molecular Pathogenesis of Alzheimer’s Disease: Reductionist versus Expansionist Approaches

By Rudy J. Castellani, Xiongwei Zhu, Hyoung-Gon Lee, Mark A. Smith and George Perry


Alzheimer’s disease (AD) is characterized clinically by dementia and pathologically by two hallmark lesions, senile plaques and neurofibrillary tangles. About a quarter century ago these hallmark lesions were purified and their protein constituents identified, precipitating an avalanche of molecular studies as well as substantial optimism about successful therapeutic intervention. In 2009, we now have copious knowledge on the biochemical cascades that produce these proteins, the different modifications and forms in which these proteins exist, and the ability to selectively target these proteins for therapeutic intervention on an experimental basis. At the same time, there has been no discernible alteration in the natural course of AD in humans. While it may be that the complexity of AD will exceed our capacity to make significant treatment progress for decades or more, a paradigm shift from the reductionism that defines amyloid-β and tau hypotheses, to one that more accurately reflects the meaning of neuropathological changes, may be warranted. We and others have demonstrated that AD pathology is a manifestation of cellular adaptation, specifically as a defense against oxidative injury. As such, AD pathology is therefore a host response rather than a manifestation of cytotoxic protein injury, and is unlikely to be a fruitful target for therapeutic intervention. An “expansionist” view of the disease, we believe, with oxidative stress as a pleiotropic and upstream process, more aptly describes the relationship between various and numerous molecular alterations and clinical disease

Topics: Review
Publisher: Molecular Diversity Preservation International (MDPI)
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2002). A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage.
  2. (1999). A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature
  3. (1999). A role for presenilin-1 in nuclear accumulation of Ire1 fragments and induction of the mammalian unfolded protein response. Cell
  4. (2006). Aging sensitizes toward ROS formation and lipid peroxidation in PS1M146L transgenic mice. Free Radic.
  5. (2002). alphaSynuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stresssignaling pathway in neuronal cells.
  6. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein.
  7. (2005). Aluminium in Alzheimer's disease: are we still at a crossroad? Cell. Mol. Life Sci.
  8. (2008). Alzheimer disease pathology as a host response.
  9. (1984). Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein.
  10. (1990). Alzheimer's disease: a conceptual history.
  11. (2004). Alzheimer's disease: intraneuronal alterations precede insoluble amyloid-beta formation.
  12. (1990). Alzheimer's disease: striatal amyloid deposits and neurofibrillary changes.
  13. (1997). Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: involvement of calcium and oxyradicals.
  14. (2002). Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study. Neurology
  15. (2008). Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol. Med.
  16. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome.
  17. (2003). Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease.
  18. (2000). Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease. Neuron
  19. (1998). Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress.
  20. (2001). Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic.
  21. (2008). Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins.
  22. (2004). Amyloid-beta precursor protein processing in neurodegeneration.
  23. (2006). Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. Neurology
  24. (2008). Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis.
  25. (2004). Antioxidant effects of statins. Drugs Today (Barc)
  26. (1996). Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid
  27. (1993). Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet
  28. (2002). Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease.
  29. (2005). Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease.
  30. (2002). Caloric intake and the risk of Alzheimer disease.
  31. (2005). Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms.
  32. (1991). Cigarette smoking-nutritional implications.
  33. (1998). Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein
  34. (2003). Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease.
  35. (2004). Cytoprotection by neutral fraction of tannat red wine against oxidative stress-induced cell
  36. (2000). Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.
  37. (2003). Diabetes, oxidative stress, and antioxidants: a review.
  38. (2003). Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice.
  39. (2002). Dietary intake of antioxidants and risk of Alzheimer disease.
  40. (1989). Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease.
  41. (2008). Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients.
  42. (2004). Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease.
  43. (1996). Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet
  44. (2003). Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells.
  45. (2004). Effects of alpha-tocopherol on an animal model of tauopathies.
  46. (2001). Elevated vulnerability to oxidative stress-induced cell death and activation of caspase-3 by the Swedish amyloid precursor protein mutation.
  47. (2001). Enhanced free radical scavenging and decreased lipid peroxidation in the rat fetal brain after treatment with ethyl docosahexaenoate.
  48. (2005). Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology
  49. (2004). FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein.
  50. (2001). Fibrillar beta-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. Neuroscience
  51. (2004). Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease.
  52. (2006). Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment.
  53. (1996). Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res.
  54. (2003). Homocysteine and oxidative stress. Amino Acids
  55. (2003). Human Abeta1-42 reduces iron-induced toxicity in rat cerebral cortex.
  56. (2002). Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans.
  57. (2005). Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice.
  58. (2000). In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification.
  59. (2002). Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease.
  60. (1996). Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature
  61. (1999). Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular
  62. (2001). Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis.
  63. (2008). Increased oxidative stress is an early pathological feature in 3xTg-AD mice. Alzheimer's and Dementia
  64. (1999). Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid beta-peptide toxicity: central roles of superoxide production and caspase
  65. (2006). Involvement of oxidative stress in Alzheimer disease.
  66. (1997). Iron accumulation in Alzheimer disease is a source of redox-generated free radicals.
  67. (2001). Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP.
  68. (2009). Lipid peroxidation and antioxidants in hyperlipidemia and hypertension.
  69. (2003). Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms.
  70. (1997). Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease.
  71. (2000). metallic, and mitotic sources of oxidative stress in Alzheimer disease.
  72. (1986). Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.
  73. (2002). Modification of brain aging and neurodegenerative disorders by genes, diet, and
  74. (1997). Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic
  75. (2007). Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway.
  76. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature
  77. (2003). Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease.
  78. (2000). Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome.
  79. (2004). Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease.
  80. (2007). Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol
  81. (1991). Neuropathological stageing of Alzheimer-related changes.
  82. (1997). Neuroprotection against oxidative stress by estrogens: structure-activity relationship.
  83. (2003). Neurotoxic mechanisms caused by the Alzheimer's disease-linked Swedish amyloid precursor protein mutation: oxidative stress, caspases, and the JNK pathway.
  84. (2000). Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature
  85. (2001). Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's
  86. (2002). Overexpression of Alzheimer's disease amyloid-beta opposes the agedependent elevations of brain copper
  87. (2003). Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathol. (Berl)
  88. (2001). Oxidative damage is the earliest event in Alzheimer disease.
  89. (1994). Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease.
  90. (2005). Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients.
  91. (2006). Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease.
  92. (2002). Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients. Free Radic.
  93. (2002). Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases.
  94. (2002). Oxidative stress in synaptosomal proteins from mutant presenilin-1 knock-in mice: implications for familial Alzheimer's disease.
  95. (2000). Oxidative stress induces increase
  96. (2000). Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry (Mosc)
  97. (2003). Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model.
  98. (1993). Oxidative stress, glutamate, and neurodegenerative disorders. Science
  99. (2002). Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease.
  100. (2004). Pathophysiology of cerebral ischemia and brain trauma: similarities and differences.
  101. (2001). Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members.
  102. (1991). Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.
  103. (1998). Plaque biogenesis in brain aging and Alzheimer's disease. II. Progressive transformation and developmental sequence of dystrophic neurites. Acta Neuropathol.
  104. (2003). Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease.
  105. (2002). Plasma homocysteine as a risk factor for dementia and Alzheimer's
  106. (2002). Potential novel targets for Alzheimer pharmacotherapy:
  107. (2001). Presenilin-1 binds cytoplasmic epithelial cadherin, inhibits cadherin/p120 association, and regulates stability and function of the cadherin/catenin adhesion complex.
  108. (1999). Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. Nat. cell biol.
  109. (2000). Prevalence of AD among whites: a summary by levels of severity. Neurology
  110. (1997). Protein phosphatase inhibitors induce modification of synapse structure and tau hyperphosphorylation in cultured rat hippocampal neurons.
  111. (2000). Reduced antioxidant enzyme activity in brains of mice transgenic for human presenilin-1 with single or multiple mutations.
  112. (1998). Regulation of brain G-protein go by Alzheimer's disease gene presenilin-1.
  113. (2000). Relation between aluminum concentrations in drinking water and Alzheimer's disease: an 8-year follow-up study.
  114. (2002). Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease.
  115. (2005). Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active
  116. (2005). Ribosome dysfunction is an early event in Alzheimer's disease.
  117. (1997). Risk of dementia among persons with diabetes mellitus: a population-based cohort study.
  118. (1996). Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's
  119. (1998). Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet
  120. (2008). Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res.
  121. (2004). Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology. Neurobiol. Aging
  122. (1990). Spin trapping of ibuprofen radicals: evidence that ibuprofen is a hydroxyl radical scavenger. Free Radic.
  123. (2003). Stroke and the risk of Alzheimer disease.
  124. (2003). Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology
  125. Sublethal RNA oxidation as a mechanism for neurodegenerative disease.
  126. (2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron
  127. (2007). Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology
  128. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy.
  129. (2003). Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology
  130. (2009). Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci.
  131. (2005). Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol. Med.
  132. (2005). Tau suppression in a neurodegenerative mouse model improves memory function. Science
  133. (2007). Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci
  134. (1968). The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.
  135. (1999). The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology
  136. (1998). The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections.
  137. (2006). The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation.
  138. (2001). The Swedish APP670/671 Alzheimer's disease mutation: the first evidence for strikingly increased oxidative injury in the temporal inferior cortex.
  139. (1991). The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease.
  140. (1907). Uber eine eigenartige Erkrankung der Hirnrinde. Allg Zeitschr Psychiatr

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.